|1.||White, Nicholas J: 23 articles (12/2014 - 01/2004)|
|2.||Dorsey, Grant: 17 articles (01/2015 - 01/2007)|
|3.||Tarning, Joel: 14 articles (08/2015 - 07/2010)|
|4.||Nosten, François: 14 articles (10/2014 - 01/2007)|
|5.||Kamya, Moses R: 13 articles (01/2015 - 01/2007)|
|6.||Rosenthal, Philip J: 12 articles (08/2015 - 01/2007)|
|7.||Lindegardh, Niklas: 12 articles (01/2014 - 06/2006)|
|8.||Kakuru, Abel: 11 articles (01/2015 - 01/2009)|
|9.||Bigira, Victor: 10 articles (01/2015 - 01/2009)|
|10.||Ashley, Elizabeth A: 10 articles (12/2014 - 11/2004)|
|1.||Falciparum Malaria (Plasmodium falciparum Malaria)
11/15/2004 - "The current dosage of DP (6.4 mg/kg DHA and 51.2 mg/kg piperaquine phosphate) given over the course of 48 h is highly effective, safe, and well tolerated for the treatment of multidrug-resistant falciparum malaria, and its efficacy is not improved by the addition of more DHA."
11/01/2012 - "Piperaquine (PQ) is part of a first-line treatment regimen for Plasmodium falciparum malaria recommended by the World Health Organization (WHO). "
03/01/2012 - "The aim of this study was to describe the pharmacokinetic and pharmacodynamic properties of piperaquine in 236 children with uncomplicated falciparum malaria in Burkina Faso. "
01/01/2012 - "The aim of this study was to investigate the population pharmacokinetics of piperaquine in pregnant and non-pregnant Sudanese women with uncomplicated Plasmodium falciparum malaria. "
09/01/2011 - "This pharmacokinetic study monitored 30 adult patients with uncomplicated falciparum malaria for 4.5 months to evaluate the effects of the concomitant intake of fat on the total piperaquine exposure. "
01/01/2009 - "The long terminal half life of piperaquine makes it suitable for intermittent preventive treatment for malaria but no studies of its use for prevention have been done in Africa. "
10/01/2015 - "The aim was to investigate the QT effect of a single dose combination regimen of piperaquine phosphate (PQP) and a novel aromatic trioxolane, OZ439, for malaria treatment. "
10/01/2015 - "Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria."
01/01/2014 - "Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria."
06/01/2013 - "Interestingly, despite strong associations, infants remained at risk for malaria, even if they had residual levels of piperaquine."
06/01/2015 - "This combination triple mutation was associated with a 5·4 times greater risk of treatment failure (hazard ratio 5·4 [95% CI 2·4-12]; p<0·0001) and higher piperaquine 50% inhibitory concentration (triple mutant 34 nM [28-41]; non-triple mutant 24 nM [1-27]; p=0·003) than other infections had. "
08/01/2011 - "The pharmacokinetic mismatching of these drugs, whose plasma half-lives are ~20 days and ~1 h, respectively, implies that recrudescent or new infections emerging shortly after treatment cessation will encounter piperaquine as a monotherapy agent. "
10/29/2014 - "Using nonlinear mixed-effects modeling, the concentration-effect relationship for the malaria-preventive effect of piperaquine was best characterized with a sigmoidal Emax relationship, where plasma concentrations of 6.7 ng/ml [relative standard error (RSE), 23%] and 20 ng/ml were found to reduce the hazard of acquiring a malaria infection by 50% [that is, median inhibitory concentration (IC50)] and 95% (IC95), respectively. "
03/01/2015 - "Recent clinical trials conducted in sub-Saharan Africa have shown that dihydroartemisinin-piperaquine (DP), a most recent ACT, may have a longer post-treatment prophylactic period and post-treatment infection period (duration of gametocyte carriage) than AL. Using epidemiological and clinical data on the efficacy of AL and DP, we developed and parameterized a mathematical transmission model that we used to compare the population-level impact of AL and DP for reducing P. "
01/01/2015 - "Mass drug administration (MDA) and focal MDA (fMDA) using dihydroartemisinin plus piperaquine (DHAp), represent two strategies to maximize the use of existing information to achieve greater clearance of human infection and reduce the parasite reservoir, and provide longer chemoprophylactic protection against new infections. "
01/01/2014 - "vivax malaria was accommodated by a constant baseline hazard (8.94 relapses/year) with the addition of a surge function in a fixed 3-week interval and a protective piperaquine effect. "
01/01/2014 - "Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in Thailand."
03/01/2004 - "Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria."
09/01/2007 - "Dihydroartemisinin-piperaquine, a fixed-dose combination antimalarial, is an inexpensive, safe and highly effective treatment for uncomplicated falciparum or vivax malaria. "
01/01/2013 - "This study aimed to synthesize available evidence on the efficacy of dihydroartemisinin-piperaquine (DHP) in treating uncomplicated Plasmodium vivax malaria in people living in endemic countries. "
01/01/1989 - "At 14-28d follow-up recrudescence was observed with asexual parasitemia in 7 of the 47 cases, showing RI resistance to piperaquine. "
11/28/2014 - "There were no significant differences in any secondary outcomes, with the exception of a lower prevalence of asymptomatic parasitemia in the dihydroartemisinin-piperaquine arm. "
12/01/2007 - "The day 28 risk of recurrent parasitemia, unadjusted by genotyping, was significantly higher for patients receiving artemether-lumefantrine than for patients receiving amodiaquine plus sulfadoxine-pyrimethamine (20.1% vs. 6.2%; risk difference, 13.8%; 95% confidence interval, 7.0%-20.7%) or dihydroartemisinin-piperaquine (20.1% vs. 2.2%; risk difference, 17.9%; 95% confidence interval, 11.6%-24.1%). "
01/01/2011 - "In high transmission settings it is probably superior to artemether-lumefantrine, artesunate plus sulphadoxine-pyrimethamine and artesunate plus amodiaquine at preventing recurrent parasitemias before day 28 (three trials, 334 participants, RR 0.20, 95% CI 0.08 to 0.49, moderate quality evidence).This advantage with dihydroartemisinin-piperaquine may last for at least six weeks even when primaquine is also given to achieve radical cure; with fewer recurrent parasitemias occurring between day 28 and day 42 (two trials, 179 participants, RR 0.21, 95% CI 0.10 to 0.46, low quality evidence).The data available from low transmission settings is too limited to make conclusions about the relative effectiveness of ACTs. "